Sale

Anti Tuberculosis Therapeutics Market

Anti Tuberculosis Therapeutics Market Size, Trends, Report: By Treatment Type: First-Line of Drugs, Second-Line of Drugs, Others; By Disease Type: Active TB, Latent TB, Others; By Diagnosis: Blood Tests, Imaging Tests, Sputum Tests, Others; By Route of Administration; By Dosage Form; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Anti Tuberculosis Therapeutics Market Outlook

The anti tuberculosis therapeutics market size was valued at USD 1354 million in 2023, driven by the increasing incidence of tuberculosis and the rising number of studies around tuberculosis therapeutics. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 2589.8 million by 2032.

 

Anti Tuberculosis Therapeutics Market Overview

Tuberculosis (TB) is caused by mycobacterium tuberculosis. Tuberculosis treatment involves a combination of antibiotics which are recommended by the healthcare professionals to the patients. These antibiotics are taken over several months to ensure the complete removal of the bacteria and prevent the development of drug-resistant strains of the disease. The standard regimen for tuberculosis treatment often includes multiple drugs to target different aspects of the infection and prevent the bacteria from becoming resistant to treatment. Some key medications used in anti-tuberculosis therapy include Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), ethambutol, streptomycin and other aminoglycosides, fluoroquinolones.

 

The anti tuberculosis therapeutics market growth is expected to grow significantly during the forecast period owing to several pivotal factors including the escalating prevalence of tuberculosis worldwide, with a stressful rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) cases in developing nations. This surge in incidences is fostering increased demand for anti-tuberculosis medications in the forecast period, propelling the market growth. Furthermore, the market growth is driven by the proactive measures by government and private organizations to spread awareness about tuberculosis.

 

Research and Development to Aid the Market Growth

The market is expected to witness significant growth in the forecast period, driven by key developments and ongoing research initiatives. For instance, the SimpliciTB trial's evaluation of the BPaMZ regimen has recently exhibited promising efficacy and treatment-shortening potential, elevating optimism and hope for effective tuberculosis management among patients and their families. Such trials are expected to drive the anti tuberculosis therapeutics market growth in the forecast period.

 

Isoniazid as a Potential Treatment for Alzheimer's Disease

Furthermore, the market growth is anticipated to be driven by the exploration of Isoniazid as a potential treatment for Alzheimer's disease presents a dual opportunity, that includes expanded therapeutic applications beyond TB treatment. Such observational research may lead to more experiments and observational studies in the market to explore the full potential of other drugs in the treatment of TB, resulting in widespread application opportunities, and bolstering the market growth.

 

Rising Efforts by Researchers to Drive the Growth

Additionally, a recent modeling study discussing the introduction of a new TB vaccine in low or middle-income countries (LMICs), concluded that it will promise substantial health and economic benefits to the anti tuberculosis therapeutics market in the countries.  These modeling studies by researchers may pull the traction of pharmaceutical and biotechnology companies to understand the urgency of the situation and create opportunities for them to fill a crucial gap in the market, likely to contribute to the anti tuberculosis therapeutics market share during the forecast period.

 

Clinical Trials to Drive Significant Development

In November 2023, TB Alliance launched a new Pan-Phase 2 clinical trial incorporating elements of Phase 2a, b, and c, identified as NC-009, to evaluate the safety and efficacy of a combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, components of TB Alliance’s BPaL regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB), one of the world’s deadliest infectious diseases. Results from preclinical and Phase 1 studies presented at the Union Conference showed that the new compound when compared with bedaquiline (a TB medicine in the same drug class), eliminated TB bacteria faster and had a potentially safer profile.

 

Such clinical trials are expected to drive the anti tuberculosis therapeutics market growth by enabling healthcare professionals to pay attention to the formulation of the TB drugs that they are prescribing to TB patients. However, this approach is also expected to provide convenience as exhibited by the results, with chances of non-compliance while improving success rates of the treatment, boosting the market growth.

 

Anti Tuberculosis Therapeutics Market Segmentations

Market Breakup by Treatment Type

  • First-Line of Drugs
  • Second-Line of Drugs
  • Others

 

Market Breakup by Disease Type

  • Active TB
  • Latent TB 
  • Others

 

Market Breakup by Diagnosis

  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

 

Market Breakup by Dosage Form

  • Tablets
  • Capsules
  • Injections
  • Others

 

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Others

 

Market Breakup by -7MM

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Anti Tuberculosis Therapeutics Market Regional Analysis

The United States has been leading the market and is likely to continue leading the market in the forecast period as well. For instance, in September 2023, the United States, through USAID, announced more than USD 23 million, as well as new efforts to support countries in fighting tuberculosis (TB) and reaching global targets set at a meeting during United Nations High Level Week. Working with Congress, the new efforts that are part of USAID’s Global Accelerator to End TB Plus package are part of more than USD 394 million in planned FY 2023 investments and illustrate USAID's steadfast commitment to ending TB globally.  Such funding activities play a crucial role in incentivizing research and deelopment in pharmaceutical companies to develop innovative therapies, drugs, and treatment modalities for TB. Such funding may also support manufacturing and the widespread distribution of drugs to fulfill a crucial gap of unmet medical needs in this domain, likely to aid the anti tuberculosis therapeutics market size in the forecast period.

 

Geographically, the Middle East and African regions are expected to lead the market growth in the forecast period. The presence of a huge patient pool and the unavailability of effective treatments are expected to provide opportunities for pharmaceutical companies and other organizations to fill a crucial gap in the market. The incidence is also expected to increase in countries that are developing with small incomes.

 

Anti Tuberculosis Therapeutics Market: Competitor Landscape

In September 2023, Global health aid agency Unitaid wrote to Johnson & Johnson's (JNJ.N) CEO, Joaquin Duato, urging "immediate action" to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives. While J&J has lowered the price of bedaquiline, which is used to treat drug-resistant tuberculosis (DR-TB), Unitaid said it was an "incomplete solution" and countries like South Africa, Belarus, and Ukraine were not benefiting.

 

The key features of the anti tuberculosis therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • AstraZeneca
  • Johnson & Johnson Private Limited 
  • Eli Lilly and Company 
  • F. Hoffmann-La Roche Ltd.  
  • Mylan N.V. 
  • Teva Pharmaceutical Industries Ltd. 
  • Sanofi 
  • Novartis 
  • Allergan 
  • Merck & Co.  
  • STI Pharma 
  • Endo International plc  
  • Fresenius Kabi AG 
  • Hikma Pharmaceuticals PLC

 

Please note that this only represents a partial' list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Disease Type
  • Diagnosis
  • Route of Administration
  • Dosage Form
  • End User
  • Region
Breakup by Treatment Type
  • First-Line of Drugs
  • Second-Line of Drugs
  • Others
Breakup by Disease Type
  • Active TB
  • Latent TB
  • Others
Breakup by Diagnosis
  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Dosage Form
  • Tablets
  • Capsules
  • Injections
  • Others
Breakup by End User
  • Hospitals
  • Speciality Clinics
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Allergan
  • Merck & Co.
  • STI Pharma
  • Endo International plc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Tuberculosis Overview
 
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Tuberculosis Epidemiology Analysis – Seven Major Markets
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Tuberculosis Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
        5.3.1    Germany Tuberculosis Epidemiology Forecast (2017-2032)
        5.3.2    France Tuberculosis Epidemiology Forecast (2017-2032)
        5.3.3    Italy Tuberculosis Epidemiology Forecast (2017-2032)
        5.3.4    Spain Tuberculosis Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Tuberculosis Epidemiology Forecast (2017-2032)
    5.4    Japan Tuberculosis Epidemiology Forecast (2017-2032)
6    Anti Tuberculosis Therapeutics Market Overview – Seven Major Markets 
    6.1    Anti Tuberculosis Therapeutics Market Historical Value (2017-2023) 
    6.2    Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
7    Anti Tuberculosis Therapeutics Market Landscape – Seven Major Markets 
    7.1    Anti Tuberculosis Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Anti Tuberculosis Therapeutics Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by End User
8    Anti Tuberculosis Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Anti Tuberculosis Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Anti Tuberculosis Therapeutics Market Segmentation   – Seven Major Markets 
    11.1    Anti Tuberculosis Therapeutics Market by Treatment Type
        11.1.1    Market Overview
        11.1.2    First-Line of Drugs
        11.1.3    Second-Line of Drugs
        11.1.4    Others
    11.2    Anti Tuberculosis Therapeutics Market by Disease Type
        11.2.1    Market Overview
        11.2.2    Active TB
        11.2.3    Latent TB
        11.2.4    Others
    11.3    Anti Tuberculosis Therapeutics Market by Diagnosis
        11.3.1    Market Overview
        11.3.2    Blood Tests
        11.3.3    Imaging Tests
        11.3.4    Sputum Tests
        11.3.5    Others
    11.4    Anti Tuberculosis Therapeutics Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Parenteral
        11.4.4    Others
    11.5    Anti Tuberculosis Therapeutics Market by Dosage Form
        11.5.1    Market Overview
        11.5.2    Tablets
        11.5.3    Capsules
        11.5.4    Injections
        11.5.5    Others
    11.6    Anti Tuberculosis Therapeutics Market by End User
        11.6.1    Market Overview
        11.6.2    Hospitals
        11.6.3    Speciality Clinics
        11.6.4    Others
    11.7    Anti Tuberculosis Therapeutics Market by Region
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
            11.7.3.1    Germany
            11.7.3.2    France
            11.7.3.3    Italy
            11.7.3.4    Spain
            11.7.3.5    United Kingdom    
        11.7.4    Japan
12    United States Anti Tuberculosis Therapeutics Market
    12.1    Anti Tuberculosis Therapeutics Market Historical Value (2017-2023) 
    12.2    Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
    12.3    Anti Tuberculosis Therapeutics Market by Disease Type
    12.4    Anti Tuberculosis Therapeutics Market by Treatment Type
13    EU-4 and United Kingdom Anti Tuberculosis Therapeutics Market
    13.1    Anti Tuberculosis Therapeutics Market Historical Value (2017-2023) 
    13.2    Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
    13.3    Germany Anti Tuberculosis Therapeutics Market Overview
        13.3.1    Anti Tuberculosis Therapeutics Market by Disease Type
        13.3.2    Anti Tuberculosis Therapeutics Market by Treatment Type
    13.4    France Anti Tuberculosis Therapeutics Market Overview
        13.4.1    Anti Tuberculosis Therapeutics Market by Disease Type
        13.4.2    Anti Tuberculosis Therapeutics Market by Treatment Type
    13.5    Italy Anti Tuberculosis Therapeutics Market Overview
        13.5.1    Anti Tuberculosis Therapeutics Market by Disease Type
        13.5.2    Anti Tuberculosis Therapeutics Market by Treatment Type
    13.6    Spain Anti Tuberculosis Therapeutics Market Overview
        13.6.1    Anti Tuberculosis Therapeutics Market by Disease Type
        13.6.2    Anti Tuberculosis Therapeutics Market by Treatment Type
    13.7    United Kingdom Anti Tuberculosis Therapeutics Market Overview
        13.7.1    Anti Tuberculosis Therapeutics Market by Disease Type
        13.7.2    Anti Tuberculosis Therapeutics Market by Treatment Type
14    Japan Anti Tuberculosis Therapeutics Market
    14.1    Anti Tuberculosis Therapeutics Market Historical Value (2017-2023) 
    14.2    Anti Tuberculosis Therapeutics Market Forecast Value (2024-2032)
    14.3    Anti Tuberculosis Therapeutics Market by Disease Type
    14.4    Anti Tuberculosis Therapeutics Market by Treatment Type
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnerships and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    AstraZeneca 
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Johnson & Johnson Private Limited
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Eli Lilly and Company
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    F. Hoffmann-La Roche Ltd. 
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Mylan N.V.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    Teva Pharmaceutical Industries Ltd.
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Sanofi
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Novartis
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    Allergan
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    Merck & Co.
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
    21.11    STI Pharma
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Endo International plc 
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic Reach and Achievements
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
    21.13    Fresenius Kabi AG
        21.13.1    Financial Analysis
        21.13.2    Product Portfolio
        21.13.3    Demographic Reach and Achievements
        21.13.4    Mergers and Acquisitions
        21.13.5    Certifications
    21.14    Hikma Pharmaceuticals PLC 
        21.14.1    Financial Analysis
        21.14.2    Product Portfolio
        21.14.3    Demographic Reach and Achievements
        21.14.4    Mergers and Acquisitions
        21.14.5    Certifications
22    Anti Tuberculosis Therapeutics Market- Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 1354 million in 2023 driven by the rising incidence of tuberculosis.

The market is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 and is likely to reach a market value of USD 2589.8 million by 2032.

The rising prevalence of tuberculosis, increased demand for better therapeutics, initiatives by government and private organizations to spread awareness, research activities, and collaboration between key players are some of the major factors driving the market growth.

Rising investments to support countries in fighting tuberculosis is a major trend influencing market growth.

The 7 major regions of the market include the United States, EU-4, the United Kingdom, and Japan.

Treatment types for tuberculosis include first-line of drugs and second line of drugs, among others.

Types of tuberculosis include active TB and latent TB, among others.

It can be diagnosed with the help of blood tests, imaging tests, and sputum tests, among others.

Oral and parenteral are the different routes of administration in the market.

End users in the market include hospitals and specialty clinics, among others.

Key players in the market include AstraZeneca, Johnson & Johnson Private Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Allergan, Merck & Co., STI Pharma, Endo International plc, Fresenius Kabi AG, and Hikma Pharmaceuticals PLC.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER